Sponsorship bias in clinical trials: growing menace or dawning realisation?
作者信息
Jefferson Tom
机构信息
Senior Associate Tutor, University of Oxford; Researcher, Nordic Cochrane Centre; Visiting Professor, Newcastle University, UK.
出版信息
J R Soc Med. 2020 Apr;113(4):148-157. doi: 10.1177/0141076820914242.
Abstract
摘要
相似文献
1
Sponsorship bias in clinical trials: growing menace or dawning realisation?
J R Soc Med. 2020 Apr;113(4):148-157. doi: 10.1177/0141076820914242.
2
Small study on industry trial sponsorship leads to big questions about quality and bias.
J Natl Cancer Inst. 2007 Jul 4;99(13):988-90. doi: 10.1093/jnci/djm057. Epub 2007 Jun 27.
3
Torcetrapib and atorvastatin--should marketing drive the research agenda?
N Engl J Med. 2005 Jun 23;352(25):2573-6. doi: 10.1056/NEJMp058075.
4
Search for evidence goes on.
BMJ. 2012 Jan 17;344:e458. doi: 10.1136/bmj.e458.
5
The Tamiflu trials.
BMJ. 2014 Apr 9;348:g2630. doi: 10.1136/bmj.g2630.
6
If the Facts Were Not Untruths, Their Implications Were: Sponsorship Bias and Misleading Communication.
Kennedy Inst Ethics J. 2018;28(2):119-144. doi: 10.1353/ken.2018.0011.
7
No evidence of industry sponsorship bias in statin trials.
BMJ. 2014 Nov 4;349:g6579. doi: 10.1136/bmj.g6579.
8
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports.
BMJ Open. 2014 Sep 30;4(9):e005253. doi: 10.1136/bmjopen-2014-005253.
9
Tug of war for antiviral drugs data.
BMJ. 2014 Apr 9;348:g2227. doi: 10.1136/bmj.g2227.
10
The statin wars.
Lancet. 2003 Nov 1;362(9394):1498. doi: 10.1016/S0140-6736(03)14698-3.
引用本文的文献
1
Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials.
Biomedicines. 2025 Feb 21;13(3):540. doi: 10.3390/biomedicines13030540.
2
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.
J Clin Med. 2025 Mar 14;14(6):1978. doi: 10.3390/jcm14061978.
3
Implementation of the EU's Health Technology Assessment regulation: where does existing methods guidance require concretization and what are the relevant methodological options?
Int J Technol Assess Health Care. 2025 Feb 6;41(1):e9. doi: 10.1017/S0266462324004793.
4
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.
Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD011762. doi: 10.1002/14651858.CD011762.pub2.
5
Conclusions of clinical trials assessing monoclonal antibodies and sponsored by pharmaceutical industry: a meta-research study.
Rev Assoc Med Bras (1992). 2024 Dec 2;70(11):e20241022. doi: 10.1590/1806-9282.20241022. eCollection 2024.
6
International Collaboration and Commercial Involvement in Randomized Controlled Trials From 10 Leading Countries, 1997 Through 2019.
Cureus. 2024 May 27;16(5):e61205. doi: 10.7759/cureus.61205. eCollection 2024 May.
7
Global Equity in Clinical Trials: An ASCO Policy Statement.
JCO Glob Oncol. 2024 Mar;10:e2400015. doi: 10.1200/GO.24.00015.
8
The quality of systematic reviews/meta-analyses assessing the effects of ankle-foot orthosis on clinical outcomes in stroke patients: A methodological systematic review.
Health Sci Rep. 2023 Mar 1;6(3):e1130. doi: 10.1002/hsr2.1130. eCollection 2023 Mar.
9
Industry influence in healthcare harms patients: myth or maxim?
Breathe (Sheff). 2022 Jun;18(2):220010. doi: 10.1183/20734735.0010-2022. Epub 2022 Jul 12.
10
Moving towards less biased research.
BMJ Open Sci. 2021 Jan 17;5(1):e100116. doi: 10.1136/bmjos-2020-100116. eCollection 2021.
本文引用的文献
1
Donald Mainland: anatomist, educator, thinker, medical statistician, trialist, rheumatologist.
J R Soc Med. 2020 Jan;113(1):28-38. doi: 10.1177/0141076819896274.
2
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Lancet. 2019 Feb 2;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1.
3
When to include clinical study reports and regulatory documents in systematic reviews.
BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11.
4
Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource.
BMJ. 2018 Sep 12;362:k3218. doi: 10.1136/bmj.k3218.
5
Statin wars: have we been misled about the evidence? A narrative review.
Br J Sports Med. 2018 Jul;52(14):905-909. doi: 10.1136/bjsports-2017-098497. Epub 2018 Jan 21.
6
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.
J Clin Epidemiol. 2017 Nov;91:95-110. doi: 10.1016/j.jclinepi.2017.07.014. Epub 2017 Aug 24.
7
The Crucial Test of Therapeutic Evidence: Torald Sollmann, M.D., Cleveland.
JAMA. 2017 Jul 18;318(3):304. doi: 10.1001/jama.2017.5060.
8
Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.
PLoS Med. 2016 Sep 20;13(9):e1002127. doi: 10.1371/journal.pmed.1002127. eCollection 2016 Sep.
9
Interpretation of the evidence for the efficacy and safety of statin therapy.
Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8.
10
Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis.
PLoS Med. 2016 Aug 16;13(8):e1002101. doi: 10.1371/journal.pmed.1002101. eCollection 2016 Aug.
Zotero 插件